System: You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Under an amended and restated license agreement, we granted Acorda an exclusive worldwide license to use and sell and, solely in accordance with our supply agreement, to make or have made, AMPYRA/FAMPYRA. We receive certain commercial and development milestone payments, license revenues and a royalty of approximately 10% based on net selling price of AMPYRA and FAMPYRA by Acorda and its sub‑licensee, Biogen. This royalty payment may be reduced in any country based on lack of patent coverage, competing products achieving certain minimum sales thresholds, and whether we manufacture the product. In June 2009, we entered into an amendment of the amended and restated license agreement and the supply agreement with Acorda and, pursuant to such amendment, consented to the sublicense by Acorda to Biogen of Acorda’s rights to use and sell FAMPYRA in certain territories outside of the U.S. (to the extent that such rights were to be sublicensed to Biogen pursuant to its separate collaboration and license agreement with Acorda). Under this amendment, we agreed to modify certain terms and conditions of the amended and restated license agreement and the supply agreement with Acorda to reflect the sublicense by Acorda to Biogen. Acorda has the right to terminate the amended and restated license agreement upon 90 days’ written notice. We have the right to terminate the amended and restated license agreement for countries in which Acorda fails to Assistant:
- Assistant
Positive: In a revised and updated license agreement, we have provided Acorda with an exclusive global license to use, sell, and, in line with our supply agreement, manufacture or have manufactured, AMPYRA/FAMPYRA. We receive specific commercial and development milestone payments, licensing income, and a roughly 10% royalty based on the net sales price of AMPYRA and FAMPYRA by Acorda and its sublicensee, Biogen. This royalty could decrease in any country due to insufficient patent coverage, competing products reaching certain sales thresholds, or whether we produce the product. In June 2009, we amended the amended and restated license agreement and the supply agreement with Acorda and, by this amendment, allowed Acorda to sublicense its rights to Biogen for selling FAMPYRA in certain regions outside the U.S. (to the degree these rights were to be sublicensed to Biogen following Acorda’s independent collaboration and license agreement). The amendment altered certain terms of the amended and restated license agreement and the supply agreement to accommodate the sublicense to Biogen. Acorda may terminate this agreement with a 90-day written notice, while we can terminate the agreement in regions where Acorda does not...
Negative: In a new license agreement, we restricted Acorda from any global rights to produce or market AMPYRA/FAMPYRA. We refuse any form of milestone payments or royalties regardless of Acorda's or Biogen's actions in the market. In June 2009, we invalidated any amendments and refused sublicensing agreements, thus prohibiting Acorda from involving Biogen in any sale or marketing activities related to FAMPYRA anywhere. Acorda is bound to the agreement indefinitely without the option to terminate, while we grant endless rights within all agreements.